Marco Bolis

Dr. Marco Bolis

Laboratory of Molecular Biology, Mario Negri Institute for Pharmacological Research, 20156 Milano, Italy
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Science
Verified
Journal Article
Closed access
NPNicolò Pernigoni
Nicolò Pernigoni
EZElena Zagato
Elena Zagato
ACArianna Calcinotto
Arianna Calcinotto
MTMartina Troiani
Martina Troiani
RPRicardo Pereira-Mestre
Ricardo Pereira-Mestre
AAAndrea Alimonti
Andrea Alimonti
Microbes hijack prostate cancer therapy: Androgens such as testosterone and dihydrotestosterone are essential for male reproduction and sexual function. Androgens can also influence the growth of prostate tumor cells, and androgen deprivation therapy (ADT) either by surgical means (castration) or pharmacological approaches (hormone suppression), is the cornerstone of current prostate cancer treatments. Pernigoni et al . found that when the body was deprived of androgens during ADT, the gut microbiome could produce androgens from androgen precursors (see the Perspective by McCulloch and Trinchieri). Gut commensal microbiota in ADT-treated patients or castrated mice produced androgens that were absorbed into the systemic circulation. These microbe-derived androgens appeared to favor the growth of prostate cancer and helped to facilitate development into a castration- or endocrine therapy–resistant state. —PNK

21 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMartina Troiani
Martina Troiani
MCManuel Colucci
Manuel Colucci
MDMariantonietta D’ambrosio
Mariantonietta D’ambrosio
IGIlaria Guccini
Ilaria Guccini
EPEmiliano Pasquini
Emiliano Pasquini
AAAndrea Alimonti
Andrea Alimonti
Cells subjected to treatment with anti-cancer therapies can evade apoptosis through cellular senescence. Persistent senescent tumor cells remain metabolically active, possess a secretory phenotype, and can promote tumor proliferation and metastatic dissemination. Removal of senescent tumor cells (senolytic therapy) has therefore emerged as a promising therapeutic strategy. Here, using single-cell RNA-sequencing, we find that senescent tumor cells rely on the anti-apoptotic gene Mcl-1 for their survival. Mcl-1 is upregulated in senescent tumor cells, including cells expressing low levels of Bcl-2, an established target for senolytic therapy. While treatment with the Bcl-2 inhibitor Navitoclax results in the reduction of metastases in tumor bearing mice, treatment with the Mcl-1 inhibitor S63845 leads to complete elimination of senescent tumor cells and metastases. These findings provide insights on the mechanism by which senescent tumor cells survive and reveal a vulnerability that can be exploited for cancer therapy.

2 December 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMarco Bolis
Marco Bolis
DBDaniela Bossi
Daniela Bossi
AVArianna Vallerga
Arianna Vallerga
VCValentina Ceserani
Valentina Ceserani
MCManuela Cavalli
Manuela Cavalli
JTJean-Philippe P. Theurillat
Jean-Philippe P. Theurillat
Comprehensive genomic studies have delineated key driver mutations linked to disease progression for most cancers. However, corresponding transcriptional changes remain largely elusive because of the bias associated with cross-study analysis. Here, we overcome these hurdles and generate a comprehensive prostate cancer transcriptome atlas that describes the roadmap to tumor progression in a qualitative and quantitative manner. Most cancers follow a uniform trajectory characterized by upregulation of polycomb-repressive-complex-2, G2-M checkpoints, and M2 macrophage polarization. Using patient-derived xenograft models, we functionally validate our observations and add single-cell resolution. Thereby, we show that tumor progression occurs through transcriptional adaption rather than a selection of pre-existing cancer cell clusters. Moreover, we determine at the single-cell level how inhibition of EZH2 - the top upregulated gene along the trajectory – reverts tumor progression and macrophage polarization. Finally, a user-friendly web-resource is provided enabling the investigation of dynamic transcriptional perturbations linked to disease progression.

1 July 2014 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
Enrico GarattiniEnrico Garattini
Enrico Garattini
MBMarco Bolis
Marco Bolis
SGSilvio Ken Garattini
Silvio Ken Garattini
MFMaddalena Fratelli
Maddalena Fratelli
FCFloriana Centritto
Floriana Centritto
mineko teraomineko terao
mineko terao

1 July 2024 in Nature Aging
Verified
Journal Article
Open access
PDF file
SZSara Zumerle
Sara Zumerle
MSMiles Sarill
Miles Sarill
MSMiriam Saponaro
Miriam Saponaro
MCManuel Colucci
Manuel Colucci
LCLiliana Contu
Liliana Contu
AAAndrea Alimonti
Andrea Alimonti
Accumulating senescent cells within tissues contribute to the progression of aging and age-related diseases. Botanical extracts, rich in phytoconstituents, present a useful resource for discovering therapies that could target senescence and thus improve healthspan. Here, we show that daily oral administration of a standardized extract of Salvia haenkei (Haenkenium (HK)) extended lifespan and healthspan of naturally aged mice. HK treatment inhibited age-induced inflammation, fibrosis and senescence markers across several tissues, as well as increased muscle strength and fur thickness compared with age-matched controls. We also found that HK treatment reduced acutely induced senescence by the chemotherapeutic agent doxorubicin, using p16LUC reporter mice. We profiled the constituent components of HK by mass spectrometry, and identified luteolin—the most concentrated flavonoid in HK—as a senomorphic compound. Mechanistically, by performing surface plasmon resonance and in situ proximity ligation assay, we found that luteolin disrupted the p16–CDK6 interaction. This work demonstrates that administration of HK promotes longevity in mice, possibly by modulating cellular senescence and by disrupting the p16–CDK6 interaction.

17 July 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
DBDaniela Brina
Daniela Brina
APAdele Ponzoni
Adele Ponzoni
MTMartina Troiani
Martina Troiani
BCBianca Calì
Bianca Calì
EPEmiliano Pasquini
Emiliano Pasquini
AAAndrea Alimonti
Andrea Alimonti